Other grades of this product :
| PD153035 HCl Basic information |
| Product Name: | PD153035 HCl | | Synonyms: | PD 153035 hydrochloride, >=98%;SU-5271 (AG1517) HCl ,ZM 252868 HCl;6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride PD153035;4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-, monohydrochloride;6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride;PD153035 Hydrochloride (ZM 252868;CS-473;PD 153035;SU 5271; AG-1517;PD-153035;SU5271; AG 1517 | | CAS: | 183322-45-4 | | MF: | C16H14BrN3O2.HCl | | MW: | 0 | | EINECS: | | Product Categories: | Inhibitors | | Mol File: | 183322-45-4.mol |
| PD153035 HCl Chemical Properties |
| Melting point | 265°C(lit.) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: soluble2mg/mL, clear (warmed) | | form | powder | | color | white to beige |
| Hazard Codes | T | | Risk Statements | 25-37/38-41 | | Safety Statements | 26-39-45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 |
| PD153035 HCl Usage And Synthesis |
| Uses | PD153035 is an inhibitor of EGFR, competitive with ATP. EGF Receptor: IC50 = 25 pM (Ki = 6 pM). | | Definition | ChEBI: A hydrochloride obtained by combining PD-153035 with one equivalent of hydrochloric acid. |
| PD153035 HCl Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye